

**AmoyDx® Pan Lung Cancer PCR Panel
Approved in Japan as a Companion Diagnostic
for trastuzumab deruxtecan**

TOKYO and XIAMEN, August 17th, 2026 — Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic (CDx) for trastuzumab deruxtecan in Japan for patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with *HER2* mutations.

Trastuzumab deruxtecan is a specifically engineered *HER2* directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being developed and commercialized by Daiichi Sankyo in Japan.

“With this approval, the AmoyDx® PLC Panel is now approved for use as a CDx to identify patients with *HER2*-mutant advanced NSCLC who may benefit from treatment with trastuzumab deruxtecan, thereby expanding their therapeutic options,” said Yuko Oi, President and CEO of Riken Genesis; Li-Mou Zheng, Ph.D., Founder and Chairman of AmoyDx; and Vivian Liu, President and CEO of PREMIA.

Developed using cutting-edge PCR technology, the AmoyDx® PLC Panel is a multiplex PCR gene detection test approved in Japan as a companion diagnostic for trastuzumab deruxtecan. Within its approved intended use in Japan, the test will enable the simultaneous detection of actionable alterations in eight key driver genes: *EGFR*, *ALK*, *ROS1*, *BRAF*, *MET* exon 14 skipping, *KRAS*, *RET* and *HER2*, which are associated with more than 20 targeted therapies for NSCLC. The panel additionally provides reference information on *NTRK1*, *NTRK2* and *NTRK3*, which are not included in its approved intended use in Japan. This approval marks a significant advancement in precision oncology, offering rapid and sensitive mutation detection that can substantially improve patient outcomes.

About Riken Genesis Co., Ltd.

RIKEN GENESIS, founded in October 2007, provides lab-assay services as well as products for genetic testing based on cutting-edge gene analysis technologies and bioinformatics, and has experience in the field of personalized medicine. The company provides highly reliable tests based on international quality standards, as demonstrated by its CLIA certification, being the first organization in Japan to meet this U.S. quality control standard for clinical laboratories. For more information, please visit www.rikengensis.jp

About Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685)

AmoyDx is at the forefront of championing molecular diagnostics for cancer, committed to enhancing patient outcomes worldwide through innovative diagnostic solutions and breaking barriers for global precision oncology adoption. The company is recognized for its excellence in precision medicine, driving advancements in cancer diagnosis through its extensive collaboration with pharmaceutical companies. For more information, please visit www.amoydiagnostics.com.

About Precision Medicine Asia (PREMIA)

PREMIA offers an integrated platform for the development of innovative oncology therapies and diagnostics in Asia, the fastest growing market for the pharmaceutical industry. Active since 2019, PREMIA has actively participated in the development and/or regulatory approval of more than 20 drugs and diagnostic products in Japan. For more information, please visit www.premia-inc.com

Contacts:

Atsushi Tsuchiya

General Manager, Medical Affairs and Marketing Department

Tel: +81-3-5759-6042

info2@rikengenesi.jp



Paul Huang

Head of International Business

info@amoydx.com



Vivian Liu

President and CEO

Tel: +81-3-5403-5973

info@premia-inc.com

